Visceral adiposity comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-05. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Trump is the first president since Grover Cleveland in 1892 to win non-consecutive terms. 2024 also marked the first time since 1892 that the incumbent party had lost in each of three consecutive presidential elections. This was the first time since 1980 that the Democrats were voted out after a single four-year term. This was also the second consecutive election in which the incumbent party had lost after a single four-year term. Trump is the first Republican to win the popular vote since George W. Bush's election in 2004; Bush and Trump are also the only two presidents who won the Electoral College while losing the popular vote in one election who then went on to win both the Electoral College and the popular vote in a subsequent election. Trump is also the first non-incumbent Republican to have won the popular vote since George H. W. Bush in 1988. Trump won a 1.48% margin of victory. While winning the popular vote, Trump did not win a majority of the popular vote; he is the first winning presidential candidate since Bill Clinton in 1996 to win the popular vote with a plurality and also the first Republican since Richard Nixon in 1968 to do so. After Cleveland in 1884 and 1892, Woodrow Wilson in 1912 and 1916, and Clinton in 1992 and 1996, Trump became the fourth president since 1880 to win two presidential elections and receive less than 50% of the popular vote in both presidential election victories. Trump is the first presidential candidate since Barack Obama in 2012 to win a second term in the White House and also the first Republican since George W.
=== EC 1.6.5 With a quinone or similar compound as acceptor === EC 1.6.5.1: deleted EC 1.6.5.2: NAD(P)H dehydrogenase (quinone) EC 1.6.5.3: now EC 7.1.1.2 NADH:ubiquinone reductase (H+-translocating) EC 1.6.5.4: monodehydroascorbate reductase (NADH) EC 1.6.5.5: NADPH:quinone reductase EC 1.6.5.6: p-benzoquinone reductase (NADPH) EC 1.6.5.7: 2-hydroxy-1,4-benzoquinone reductase EC 1.6.5.8: Now EC 7.2.1.1, NADH:ubiquinone reductase (Na+-transporting) EC 1.6.5.9: NADH:ubiquinone reductase (non-electrogenic) EC 1.6.5.10: NADPH dehydrogenase (quinone) EC 1.6.5.11: Identical to EC 1.6.5.9, NADH:quinone reductase (non-electrogenic) EC 1.6.5.12: demethylphylloquinone reductase
==== Forms ==== Two forms of colistin are available commercially: colistin sulfate and colistimethate sodium (colistin methanesulfonate sodium, colistin sulfomethate sodium). Colistin sulfate is cationic; colistimethate sodium is anionic. Colistin sulfate is stable, whereas colistimethate sodium is readily hydrolysed to a variety of methanesulfonated derivatives. Colistin sulfate and colistimethate sodium are eliminated from the body by different routes. With respect to Pseudomonas aeruginosa, colistimethate is the inactive prodrug of colistin. The two drugs are not interchangeable.
Sources: en.wikipedia.org
There is high interindividual variability in the levels of estradiol achieved with oral estradiol, which is likely related to the high first-pass effect. This variation has been reported to be in the range of 28 to 127%, or about 4.6-fold maximal difference in levels between individuals, in terms of mean area-under-the-curve levels of estradiol. In postmenopausal women, a dosage of 1 mg/day oral micronized estradiol has been found to produce circulating concentrations of 30 to 50 pg/mL estradiol and 150 to 300 pg/mL estrone, while a dosage of 2 mg/day has been found to result in circulating levels of 50 to 180 pg/mL estradiol and 300 to 850 pg/mL estrone. A study of oral micronized estradiol in transgender women found that mean estradiol levels across a dosage range of 1 to 8 mg/day were about 50 pg/mL at 1 mg/day, 100 pg/mL at 4 mg/day, and 150 pg/mL at 8 mg/day, with a wide degree of variation. In another study, mean estradiol levels at steady state with 4 mg/day and 6 mg/day oral micronized estradiol were approximately 180 pg/mL and 265 pg/mL, respectively. A study that used high to very high-dose oral micronized estradiol in postmenopausal women found that steady-state estradiol levels with 6 mg/day were about 300 pg/mL and with 30 mg/day were about 2,400 pg/mL. Estradiol valerate is rapidly hydrolyzed into estradiol in the intestines. For this reason, oral estradiol and oral estradiol valerate have very similar pharmacokinetics.
In 1897, portions of an octopus, said to have been more gigantic than any ever before seen, were washed up on the beach at St. Augustine. Prof. Verrill, of Yale University, who examined the remains, which alone reputedly weighed over six tons, calculated that the living creature had a girth of 25 feet and tentacles 72 feet in length! He learned that a sample of the integument was preserved in the Smithsonian Institution, and persuaded the curators to send a portion of the sample to his colleague, Dr. Joseph F. Gennaro Jr., a cell biologist at the University of Florida. Gennaro compared the connective tissue of the St. Augustine carcass to control specimens from known octopus and squid species. He published his findings in the March 1971 issue of Natural History:
In Natal, the Battle of the Tugela Heights, which started on 14 February was Buller's fourth attempt to relieve Ladysmith. The losses Buller's troops had sustained convinced Buller to adopt Boer tactics "in the firing line—to advance in small rushes, covered by rifle fire from behind; to use the tactical support of artillery; and above all, to use the ground, making rock and earth work for them as it did for the enemy." Despite reinforcements his progress was painfully slow against stiff opposition. However, on 26 February, after much deliberation, Buller used all his forces in one all-out attack for the first time and succeeded in forcing a crossing of the Tugela to defeat Botha's outnumbered forces north of Colenso. After a siege lasting 118 days, the Relief of Ladysmith was effected, the day after Cronjé surrendered, but at a total cost of 7,000 British casualties. Buller's troops marched into Ladysmith on 28 February. After a succession of defeats, the Boers realised that against such overwhelming numbers of troops, they had little chance and became demoralised. Roberts then advanced into the Orange Free State from the west, putting the Boers to flight at the Battle of Poplar Grove and capturing Bloemfontein, the capital, unopposed on 13 March with the Boer defenders escaping and scattering. Meanwhile, he detached a small force to relieve Baden-Powell. The Relief of Mafeking on 18 May 1900 provoked riotous celebrations in Britain, the origin of the Edwardian slang word "mafficking". On 28 May, the Orange Free State was annexed and renamed the Orange River Colony.
Sources: en.wikipedia.org
A variety of medical and psychological conditions have been misdiagnosed as anorexia nervosa; in some cases the correct diagnosis was not made for more than ten years. The distinction between binge purging anorexia, bulimia nervosa and Other Specified Feeding or Eating Disorders (OSFED) is often difficult for non-specialist clinicians. A main factor differentiating binge-purge anorexia from bulimia is the gap in physical weight. Patients with bulimia nervosa are ordinarily at a healthy weight, or slightly overweight. Patients with binge-purge anorexia are commonly underweight. Moreover, patients with the binge-purging subtype may be significantly underweight and typically do not binge-eat large amounts of food. In contrast, those with bulimia nervosa tend to binge large amounts of food. It is not unusual for patients with an eating disorder to "move through" various diagnoses as their behavior and beliefs change over time.
==== Eliminated in primary ==== Earnest Clayton, public health professional Peter Filler, teacher and nominee for the 2nd district in 2024 Todd Ivey, physician Marty Rocha, deputy sheriff and nominee for Texas's 28th House of Representatives district in 2024 Terry Virts, retired United States Air Force pilot and NASA astronaut (previously ran for U.S. Senate)
The human body is composed of elements including hydrogen, oxygen, carbon, calcium and phosphorus. These elements reside in trillions of cells and non-cellular components of the body. The adult male body is about 60% total body water content of some 42 litres (9.2 imp gal; 11 US gal). This is made up of about 19 litres (4.2 imp gal; 5.0 US gal) of extracellular fluid including about 3.2 litres (0.70 imp gal; 0.85 US gal) of blood plasma and about 8.4 litres (1.8 imp gal; 2.2 US gal) of interstitial fluid, and about 23 litres (5.1 imp gal; 6.1 US gal) of fluid inside cells. The content, acidity and composition of the water inside and outside cells is carefully maintained. The main electrolytes in body water outside cells are sodium and chloride, whereas within cells it is potassium and other phosphates.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.